Evre III MRONJ Tedavisinde Pentoksifilin ve Tokoferol Protokolü: Bir Olgu Sunumu

Yıl 2023, Cilt: 2 Sayı: 3, 162 - 167, 30.12.2023

Selen Elif Merey Mehmet Demiray Öznur Özalp Alper Sindel Mehmet Ali Altay

Öz

Pentoksifilin ve tokoferol rejiminin osteoradyonekrozun önlenmesi ve tedavisinde olumlu sonuçları bildirilmekle beraber, MRONJ tedavisindeki rolü ile ilgili çalışmaların sayısı limitlidir. Bu vaka raporunda, patolojik mandibula fraktürü gelişmiş ve cerrahi tedavi uygulanamayan bir evre III MRONJ olgusunda PENTO protokolü ile elde edilen sonuçlar sunulacaktır.
68 yaşında prostat kanseri ve üç yıllık intravenöz zoledronik asit kullanım öyküsü bulunan erkek hasta, 2018 yılında kliniğimize iyileşmeyen çekim bölgesi şikâyeti ile başvurmuştur. Takip ve kontrol bakımından kooperasyon kurulamayan hastada, iki yıl sonra patolojik mandibula fraktürü gözlenmiştir. Hastanın devam eden kemoterapisi göz önünde bulundurularak, PENTO protokolüne başlanmış, yedi aylık sürenin sonunda hastada spontan sekestrasyon, kırık hattında iyileşme ve yumuşak dokuda kapanma izlenmiştir.
Bu vakadan elde edilen bulgular ve mevcut literatür değerlendirildiğinde, PENTO protokolü MRONJ yönetiminde umut vaat eden bir tedavi yaklaşımı olarak düşünülebilir. Bununla birlikte, bu rejimin MRONJ tedavisindeki yerinin daha net bir biçimde aydınlatılması için, daha geniş hasta gruplarını içeren ileri klinik ve deneysel araştırmalara ihtiyaç vardır.

Anahtar Kelimeler

MRONJ, patolojik fraktür, PENTO, pentoksifilin, tokoferol

Pentoxifylline and Tocopherol in the Management of Stage III Medication-Related Osteonecrosis of the Jaw: A Case Report

Öz

Regimen of pentoxifylline and tocopherol (PENTO) has been widely recommended in prevention and treatment of osteoradionecrosis, however, limited data has been found regarding the efficacy of this protocol in management of MRONJ. This report aims to present the outcomes of PENTO protocol in a stage III MRONJ case with pathologic mandible fracture who was not convenient for surgery.
A 68-year-old male patient with prostate cancer and a three-year history of intravenous zoledronic acid was referred to our clinic for impaired healing of extraction site in mandible in 2018. He was non-cooperated for follow-up and control appointments and two years later from the first visit, it was observed that a pathologic fracture occured in the region. Due to the ongoing chemotherapy of the patient, PENTO protocol was initiated. At the end of a seven-month period, spontaneous sequestration, healing of the fracture and healing of the mucosa was observed.
Findings of the presented case and current literature suggest that PENTO protocol may be a promising treatment modality in MRONJ management. However, further clinical and experimental research involving larger sample size is necessary to clarify the role of this regimen in the treatment of MRONJ.

Anahtar Kelimeler

MRONJ, pathologic fracture, PENTO, pentoxifylline, tocopherol

Kaynakça

• 1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-56.
• 2. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2-12.
• 3. Pichardo SEC, Ten Broek FW, Richard van Merkesteyn JP. Treatment of pathologic fractures of the mandible in stage III medication-related osteonecrosis of the jaw-an observational study. J Craniomaxillofac Surg. 2018;46(8):1241-6.
• 4. Moll S, Mueller S, Meier JK, Reichert TE, Ettl T, Klingelhoffer C. Patients' quality of life improves after surgical intervention of stage III medication-related osteonecrosis of the jaw. Oral Maxillofac Surg. 2021;25(3):359-66.
• 5. Ristow O, Ruckschloss T, Bodem J, Berger M, Bodem E, Kargus S, et al. Double-layer closure techniques after bone surgery of medication-related osteonecrosis of the jaw - A single center cohort study. J Craniomaxillofac Surg. 2018;46(5):815-24.
• 6. Delanian S, Lefaix J-L. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiotherapy and oncology. 2004;73(2):119-31.
• 7. Delanian S, Depondt J, Lefaix JL. Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck. 2005;27(2):114-23.
• 8. Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys. 2011;80(3):832-9.
• 9. Martos-Fernández M, Saez-Barba M, López-López J, Estrugo-Devesa A, Balibrea-del-Castillo JM, Bescós-Atín C. Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. Oral surgery, oral medicine, oral pathology and oral radiology. 2018;125(5):431-9.
• 10. Goker F, Grecchi E, Grecchi F, Francetti L, Del Fabbro M. Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. Eur Rev Med Pharmacol Sci. 2021;25(6):2662-73.
• 11. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.
• 12. Sakkas A, Heil S, Kargus S, Rebel M, Mischkowski RA, Thiele OC. Tocilizumab: Another medication related to osteonecrosis of the jaws? A case report and literature review. GMS Interdiscip Plast Reconstr Surg DGPW. 2021;10:Doc03.
• 13. Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015;44(5):568-85.
• 14. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery. 2005;63(11):1567-75.
• 15. Vanpoecke J, Verstraete L, Smeets M, Ferri J, Nicot R, Politis C. Medication-related osteonecrosis of the jaw (MRONJ) stage III: Conservative and conservative surgical approaches versus an aggressive surgical intervention: A systematic review. J Craniomaxillofac Surg. 2020;48(4):435-43.
• 16. Breik O, Tocaciu S, Briggs K, Tasfia Saief S, Richardson S. Is there a role for pentoxifylline and tocopherol in the management of advanced osteoradionecrosis of the jaws with pathological fractures? Case reports and review of the literature. Int J Oral Maxillofac Surg. 2019;48(8):1022-7.
• 17. Heifetz-Li JJ, Abdelsamie S, Campbell CB, Roth S, Fielding AF, Mulligan JP. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral surgery, oral medicine, oral pathology and oral radiology. 2019;128(5):491-7. e2.
• 18. Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(5):593-6.
• 19. Owosho AA, Estilo CL, Huryn JM, Yom SK. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(4):455-9.
• 20. Kolokythas A, Rasmussen JT, Reardon J, Feng C. Management of osteoradionecrosis of the jaws with pentoxifylline-tocopherol: a systematic review of the literature and meta-analysis. Int J Oral Maxillofac Surg. 2019;48(2):173-80.
• 21. Lovin BD, Choi JS, Lindquist NR, Phan J, Gidley PW, Nader ME. Pentoxifylline and Tocopherol in the Management of Temporal Bone Osteoradionecrosis: A Case Series. Otol Neurotol. 2020;41(10):1438-46.
• 22. de Carvalho EF, Bertotti M, Migliorati CA, Rocha AC. Cilostazol and Tocopherol in the Management of Medication-Related Osteonecrosis of the Jaw: New Insights From a Case Report. J Oral Maxillofac Surg. 2021;79(12):2499-506.
• 23. Paiva GLA, de Campos WG, Rocha AC, Junior CAL, Migliorati CA, Dos Santos Silva AR. Can the prophylactic use of pentoxifylline and tocopherol before dental extractions prevent osteoradionecrosis? A systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023.